Reference health

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction

https://doi.org/10.1016/s0090-4295(02)01686-2
CiteStamped reference-health badge
1 of 39 checkable references need attention · checked 2026-07-22

At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.

9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

References needing attention

does not resolve to a known work10.1001/archinte.150.4.745
The 38 checked references that resolve
resolves10.3181/00379727-211-43950A
Nitric Oxide and Cyclic GMP Signaling
resolves10.1016/S1350-9462(00)00014-8
Vertebrate Photoreceptors
resolves10.1074/jbc.274.20.13729
Cyclic GMP Phosphodiesterase-5: Target of Sildenafil
resolves10.1023/A:1020150124721
Nitric Oxide: A Unique Endogenous Signaling Molecule in Vascular Biology
resolves10.1056/NEJM200006153422407
Erectile Dysfunction
resolves10.1095/biolreprod52.3.485
Role of Nitric Oxide in the Physiology of Erection1
resolves10.1016/0006-291X(90)92168-Y
Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle
resolves10.1007/BFb0033668
Mechanisms of regulation and functions of guanylyl cyclases
resolves10.1016/S0024-3205(98)00259-8
cGMP mediates corpus cavernosum smooth muscle relaxation with altered cross-bridge function
resolves10.1016/S0079-6603(00)65001-8
Cyclic nucleotide phosphodiesterases: Relating structure and function
resolves10.1152/physrev.1995.75.4.725
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms
resolves10.1016/S0002-9149(99)00042-9
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
resolves10.1046/j.1432-1327.2001.02233.x
Allosteric sites of phosphodiesterase‐5 (PDE5)
resolves10.1016/S0022-5347(01)63299-3
EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES
resolves10.1097/00005344-200112000-00016
Cardiac Electrophysiologic and Hemodynamic Effects of Sildenafil, a PDE5 Inhibitor, in Anesthetized Dogs
resolves10.1016/S0090-4295(99)00371-4
Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
resolves10.1096/fj.00-0538com
Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure
resolves10.1016/S0024-3205(98)00158-1
Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
resolves10.1038/sj.ijir.3900726
The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
resolves10.1016/S0024-3205(01)01308-X
Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor
resolves10.1046/j.1432-1327.2000.01297.x
Phosphorylation of phosphodiesterase‐5 by cyclic nucleotide‐dependent protein kinase alters its catalytic and allosteric cGMP‐binding activities
resolves10.1080/004982599238687
Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man
resolves10.1046/j.0306-5251.2001.00033.x
The effects of sildenafil on human sperm function in healthy volunteers
resolves10.1056/NEJM199805143382001
Oral Sildenafil in the Treatment of Erectile Dysfunction
resolves10.1016/S0002-9149(99)00044-2
Sildenafil citrate and blood-pressure–lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist
resolves10.1016/S0735-1097(00)00705-1
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
resolves10.1161/01.CIR.99.1.168
Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease
resolves10.1016/S0002-9149(99)00043-0
Effects of sildenafil citrate on human hemodynamics
resolves10.1038/sj.ijir.3900354
Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction
resolves10.1046/j.0306-5251.2001.00032.x
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
resolves10.1046/j.0306-5251.2001.00027.x
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality
resolves10.1046/j.1365-2125.2001.00318.x
Identification of the cytochrome P450 enzymes involved in the <i>N</i>‐demethylation of sildenafil
resolves10.1046/j.0306-5251.2001.00031.x
The effects of steady‐state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers
resolves10.1046/j.0306-5251.2001.00030.x
The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers
resolves10.1016/S0002-9149(99)00046-6
Overall cardiovascular profile of sildenafil citrate
resolves10.1046/j.1365-2125.2000.00245.x
Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir
resolves10.1046/j.0306-5251.2001.00029.x
The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil
resolves10.1046/j.0306-5251.2001.00034.x
Onset and duration of action of sildenafil for the treatment of erectile dysfunction
The 9 references without a DOI — listed, not checked
no DOI — not checkedGuanylyl cyclases and signaling by cyclic GMP
no DOI — not checkedSelectivity of sildenafil citrate and other phosphodiesterase type 5 (PDE5) inhibitors against human phosphodiesterase types 7-11
no DOI — not checkedSildenafil
no DOI — not checked10.1016/S0090-4295(02)01686-2_BIB25
no DOI — not checkedCharacterisation of retinal phosphodiesterase (PDE) isozymes and the effects of sildenafil in vitro
no DOI — not checked10.1016/S0090-4295(02)01686-2_BIB34
no DOI — not checkedOcular safety of Viagra (sildenafil citrate)
no DOI — not checkedPharmacokinetics of sildenafil (VIAGRA), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers
no DOI — not checkedThe effects of sildenafil citrate (VIAGRA) on color discrimination in volunteers and patients with erectile dysfunction
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1016/s0090-4295(02)01686-2"><img src="https://citestamp.com/citestamped/10.1016/s0090-4295(02)01686-2/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1016/s0090-4295(02)01686-2/badge.svg)](https://citestamp.com/citestamped/10.1016/s0090-4295(02)01686-2)